Pulmonary pharmacology & therapeutics最新文献

筛选
英文 中文
The incidence and prognosis of other iatrogenic immunodeficiency-associated lymphoproliferative disorders of the lung related to methotrexate: A retrospective study 与甲氨蝶呤有关的其他先天性免疫缺陷相关肺部淋巴组织增生性疾病的发病率和预后:一项回顾性研究。
IF 3.2 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2024-03-11 DOI: 10.1016/j.pupt.2024.102297
Atsushi Torii , Masahide Oki , Hiroatsu Iida , Arisa Yamada , Yoshihito Kogure , Chiyoe Kitagawa , Hideo Saka
{"title":"The incidence and prognosis of other iatrogenic immunodeficiency-associated lymphoproliferative disorders of the lung related to methotrexate: A retrospective study","authors":"Atsushi Torii ,&nbsp;Masahide Oki ,&nbsp;Hiroatsu Iida ,&nbsp;Arisa Yamada ,&nbsp;Yoshihito Kogure ,&nbsp;Chiyoe Kitagawa ,&nbsp;Hideo Saka","doi":"10.1016/j.pupt.2024.102297","DOIUrl":"10.1016/j.pupt.2024.102297","url":null,"abstract":"<div><h3>Background and objective</h3><p>Other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPD) are rare but well-known diseases that manifest during or after methotrexate (MTX) administration. Limited information is available on the clinical characteristics of OIIA-LPD of the lung because only a few cases have been reported. Thus, we aimed to assess the incidence and prognosis of patients with OIIA-LPD of the lung.</p></div><div><h3>Methods</h3><p>Patients with OIIA-LPD of the lung treated at our institution between January 2008 and July 2020 were retrospectively analysed.</p></div><div><h3>Results</h3><p>Among the 51 patients with OIIA-LPD, 16 (31.3%, 7 men, 9 women) had OIIA-LPD of the lung (median age, 69 [range, 63–82] years). Peripheral lesions were observed in 10 (62.5%), central lesions in two (12.5%), and both lesions in four (25.0%) patients. Nine of the 16 patients underwent bronchoscopic biopsy, seven were diagnosed (diagnostic yield, 77.8%) and, re-biopsy was performed in 2 patients. Eight (50.0%) patients had LPD and six (37.5%) had diffuse large B-cell lymphoma. In the 14 patients with confirmed treatment efficacy, the overall response rate to MTX withdrawal was 71.4%. However, chemotherapy was required in case of larger lesions (three patients). Death related to OIIA-LPD occurred in only one patient, and 11 of the 14 patients were alive during the study period (median follow-up time, 53.7 [range, 4.3–84.2] months).</p></div><div><h3>Conclusion</h3><p>The incidence of OIIA-LPD of the lung is 31.3% and higher than that reported previously. The treatment effect of MTX withdrawal seems to be sufficient; however, in some cases, chemotherapy may be required from the beginning.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"85 ","pages":"Article 102297"},"PeriodicalIF":3.2,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140102340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between pre-ICU aspirin administration and ARDS mortality in the MIMIC-IV database: A cohort study MIMIC-IV 数据库中重症监护病房前阿司匹林用药与 ARDS 死亡率之间的关系:一项队列研究。
IF 3.2 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2024-03-08 DOI: 10.1016/j.pupt.2024.102288
Yi Yu , Dengcan Yang , Qianqian Wang , Jian Li
{"title":"Association between pre-ICU aspirin administration and ARDS mortality in the MIMIC-IV database: A cohort study","authors":"Yi Yu ,&nbsp;Dengcan Yang ,&nbsp;Qianqian Wang ,&nbsp;Jian Li","doi":"10.1016/j.pupt.2024.102288","DOIUrl":"10.1016/j.pupt.2024.102288","url":null,"abstract":"<div><h3>Background</h3><p>Acute Respiratory Distress Syndrome (ARDS) is a severe condition with high mortality and morbidity rates. Evidence on the effectiveness of pharmacological interventions for ARDS treatment is limited. Recent studies suggest that aspirin may prevent ARDS development, but its efficacy in established ARDS is uncertain.</p></div><div><h3>Methods</h3><p>We enrolled patients with ARDS using data from the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database. Primary outcomes were 30- and 90-day mortality rates and length of ICU stay. We employed multivariable Cox regression and linear regression models for statistical analysis and used propensity score matching (PSM) to ensure robust results.</p></div><div><h3>Results</h3><p>The study included 10,042 participants with an average age of 61.8 ± 15.3 years. Kaplan–Meier analysis showed significantly lower 30- and 90-day mortality rates in patients treated with pre-ICU admission aspirin compared with non-aspirin use (<em>p</em> &lt; 0.0001). Multivariable Cox regression models revealed a significant 63% reduction in 30-day mortality for pre-ICU aspirin users (HR = 0.37, 95% CI: 0.31–0.44, <em>p</em> &lt; 0.001). Aspirin use in the ICU was associated with a 59% reduction in ICU mortality and a 0.68-day reduction in length of ICU stay (<em>p</em> &lt; 0.05). These findings consistently indicate that aspirin may improve survival in patients with ARDS, even after further stratification of aspirin use and PSM analysis.</p></div><div><h3>Conclusion</h3><p>Our findings suggest that aspirin treatment before ICU admission is associated with significantly reduced 30- and 90-day mortality rates and decreased length of ICU stay in patients with ARDS.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"85 ","pages":"Article 102288"},"PeriodicalIF":3.2,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140068659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study 特发性肺纤维化患者抗纤维化治疗的耐受性和疗效:一项真实世界研究的结果
IF 3.2 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2024-01-17 DOI: 10.1016/j.pupt.2024.102287
Ruiming Zhao , Bingbing Xie , Xin Wang , Xinran Zhang , Yanhong Ren , Chen Wang , Huaping Dai
{"title":"The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study","authors":"Ruiming Zhao ,&nbsp;Bingbing Xie ,&nbsp;Xin Wang ,&nbsp;Xinran Zhang ,&nbsp;Yanhong Ren ,&nbsp;Chen Wang ,&nbsp;Huaping Dai","doi":"10.1016/j.pupt.2024.102287","DOIUrl":"10.1016/j.pupt.2024.102287","url":null,"abstract":"<div><h3>Background</h3><p>Idiopathic pulmonary fibrosis<span><span><span> is a progressive and fatal lung disease lacking effective therapeutics. </span>Treatment<span><span> with pirfenidone or </span>nintedanib is recommended for patients to delay the progression of their disease. Adverse reactions caused by anti-fibrosis </span></span>drugs can sometimes interrupt treatment and even change the progression of the disease.</span></p></div><div><h3>Objective</h3><p><span>This study aimed to investigate the clinical use, adverse reactions, tolerability of pirfenidone and nintedanib </span>in patients<span> with idiopathic pulmonary fibrosis and the efficacy of antifibrotic therapy in a real world.</span></p></div><div><h3>Methods</h3><p>We recruited patients with idiopathic pulmonary fibrosis treated with pirfenidone or nintedanib at China-Japan Friendship Hospital from February 2017 to February 2022. We investigated the medication situation, adverse reactions, tolerability and survival of patients taking medications.</p></div><div><h3>Results</h3><p>A total of 303 patients with idiopathic pulmonary fibrosis were enrolled in the study. Treatment was divided between 205 patients receiving pirfenidone and 98 patients receiving nintedanib. Baseline data between the two groups were not significantly different. Patients treated with nintedanib had a higher overall discontinuation rate than those treated with pirfenidone (61.22 vs. 32.68 %, <em>p</em> &lt; 0.001). Across all patient groups, the most common reason for discontinuing treatment was medication-related adverse effects. Compared to pirfenidone, nintedanib had a significantly higher discontinuation rate due to adverse events (48.98 % vs 27.80 %, <em>p</em> &lt; 0.001). The most common side effect of both drugs was diarrhea. Pirfenidone was associated with a higher rate of extra-digestive adverse effects than nintedanib. Survival was not significantly different between the two drugs and using pirfenidone above 1200 mg/day did not confer significant survival benefits. The survival rate of patients who adhere to anti-fibrosis therapy for more than 6 months can be significantly improved (HR = 0.323, <em>p</em> = 0.0015).</p></div><div><h3>Conclusion</h3><p>Gastrointestinal adverse effects were the most common adverse effects and the main reason of discontinuation of antifibrotic therapy, especially nintedanib. Consistent adherence to antifibrotic therapy may make the patients benefit from adjusting their antifibrotic medications, dosage, and active management of side effects.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"84 ","pages":"Article 102287"},"PeriodicalIF":3.2,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139495753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epithelial IL5RA promotes epithelial-mesenchymal transition in pulmonary fibrosis via Jak2/STAT3 cascade 上皮细胞 IL5RA 通过 Jak2/STAT3 级联促进肺纤维化中的上皮-间质转化
IF 3.2 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2024-01-06 DOI: 10.1016/j.pupt.2024.102286
Shuyun Chen, Tiantian Zhao, Shiguang Xie, Xuan Wan
{"title":"Epithelial IL5RA promotes epithelial-mesenchymal transition in pulmonary fibrosis via Jak2/STAT3 cascade","authors":"Shuyun Chen,&nbsp;Tiantian Zhao,&nbsp;Shiguang Xie,&nbsp;Xuan Wan","doi":"10.1016/j.pupt.2024.102286","DOIUrl":"10.1016/j.pupt.2024.102286","url":null,"abstract":"<div><p><span>Pulmonary fibrosis<span><span> is a progressive and debilitating lung disease characterized by the excessive accumulation of </span>extracellular matrix<span><span> (ECM) components within the lung parenchyma. However, the underlying mechanism remains largely elusive, and the </span>treatment<span> options available for pulmonary fibrosis are limited. Interleukin 5 receptor, alpha (IL5RA) is a well-established regulator of eosinophil<span> activation, involved in eosinophil-mediated anti-parasitic activities and allergic reactions<span>. Recent studies have indicated additional roles of IL5RA in lung epithelium and fibroblasts. Nevertheless, its involvement in pulmonary fibrosis remains unclear. In present study, we employed single-cell analyses alongside molecular and cellular assays to unveil the expression of IL5RA in lung epithelial cells. Moreover, using both </span></span></span></span></span></span><em>in vitro</em> and <em>in vivo</em> models, we demonstrated a notable upregulation of epithelial IL5RA during the progression of pulmonary fibrosis. This upregulated IL5RA expression subsequently promotes epithelial-mesenchymal transition (EMT), leading to the generation of mesenchymal phenotype with augmented capability for ECM production. Importantly, our findings uncovered that the pro-fibrotic function of IL5RA is mediated by Jak2/STAT3 signaling cascades. Inhibiting IL5RA has the potential to deactivate Jak2/STAT3 and suppress the downstream EMT process and ECM production, thereby offering a promising therapeutic strategy for pulmonary fibrosis.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"84 ","pages":"Article 102286"},"PeriodicalIF":3.2,"publicationDate":"2024-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139376037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tanshinone IIA alleviates bleomycin-induced pulmonary fibrosis by inhibiting Zbtb16 丹参酮 IIA 通过抑制 Zbtb16 减轻博莱霉素诱导的肺纤维化
IF 3.2 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2024-01-06 DOI: 10.1016/j.pupt.2024.102285
Huijuan Zhang, Jianli Qiu, Qianyi Zhao, Yong Zhang, Haitao Zheng, Ziying Dou, Yongbin Yan
{"title":"Tanshinone IIA alleviates bleomycin-induced pulmonary fibrosis by inhibiting Zbtb16","authors":"Huijuan Zhang,&nbsp;Jianli Qiu,&nbsp;Qianyi Zhao,&nbsp;Yong Zhang,&nbsp;Haitao Zheng,&nbsp;Ziying Dou,&nbsp;Yongbin Yan","doi":"10.1016/j.pupt.2024.102285","DOIUrl":"10.1016/j.pupt.2024.102285","url":null,"abstract":"<div><p><span>Pulmonary fibrosis<span><span><span> is a complex disease that can occur in a variety of clinical settings. The Zinc Finger<span> and BTB Domain Containing 16 (Zbtb16) is a transcription factor and has not been studied in pulmonary fibrosis. Lung tissues from rats which were treated with </span></span>bleomycin and </span>Tanshinone IIA<span><span><span> (Tan IIA) were collected for mRNA sequencing. Zbtb16, a differentially expressed gene, was screened. Using adeno-associated virus to knock down Zbtb16 in rats, it was found that the lung index and the content of hydroxyproline in lung tissue were decreased. HE and Masson staining revealed that pathological symptoms of lung </span>histopathology<span> were relieved after Zbtb16 knockdown. Protein expressions of α-SMA, Collagen I and </span></span>Fibronectin were significantly decreased after Zbtb16 knockdown </span></span></span><em>in vivo</em> and <em>in vitro</em><span>. Meanwhile, the protein content of TGF-β1 and the phosphorylation of Smad2/3 were inhibited by Zbtb16 knockdown. Conversely, under the treatment<span> of Tan IIA and TGF-β1, overexpression of Zbtb16 improved cell viability, increased the expression of fibrosis-related proteins, and promoted the phosphorylation of Smad 2/3. All above demonstrates that Zbtb16 inhibition ameliorates pulmonary fibrosis and suppresses the TGF-β/Smad pathway. Furthermore, Zbtb16 mediates the inhibitory process of Tan IIA on pulmonary fibrosis. This study provides a novel candidate therapeutic target for pulmonary fibrosis.</span></span></p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"84 ","pages":"Article 102285"},"PeriodicalIF":3.2,"publicationDate":"2024-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ferroptosis mediates airway epithelial E-cadherin dysfunction in LPS-induced acute lung injury 铁蛋白沉积介导 LPS 诱导的急性肺损伤中气道上皮 E-cadherin 功能障碍
IF 3.2 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2023-12-27 DOI: 10.1016/j.pupt.2023.102284
Zemin Chen , Haixiong Tang , Sudan Gan , Changyun Yang , Shiyue Li , Jing Li , Lihong Yao
{"title":"Ferroptosis mediates airway epithelial E-cadherin dysfunction in LPS-induced acute lung injury","authors":"Zemin Chen ,&nbsp;Haixiong Tang ,&nbsp;Sudan Gan ,&nbsp;Changyun Yang ,&nbsp;Shiyue Li ,&nbsp;Jing Li ,&nbsp;Lihong Yao","doi":"10.1016/j.pupt.2023.102284","DOIUrl":"10.1016/j.pupt.2023.102284","url":null,"abstract":"<div><h3>Background</h3><p>Loss of E-cadherin in the airway epithelial cells is a critical contributor to the development of ALI/ARDS. Yet the underlying mechanisms are largely unknown. Increasing evidences have revealed the significance of ferroptosis in the pathophysiological process of ALI/ARDS. The aim of this study was to investigate the role of ferroptosis in dysregulation of airway epithelial E-cadherin in ALI/ARDS.</p></div><div><h3>Methods</h3><p><span>BALB/c mice were subjected to intratracheal instillation of </span>lipopolysaccharide<span><span> (LPS) to establish an ALI model. Two inhibitors of ferroptosis, liproxstatin-1 (Lip-1, at the dose of 10 mg/kg and 30 mg/kg) and ferrostatin-1 (Fer-1, at the dose of 1 mg/kg and 5 mg/kg), were respectively given to the mice through </span>intraperitoneal injection after LPS challenge. The expression of ferroptotic markers, full-length E-cadherin and soluble E-cadherin (sE-cadherin) were both detected.</span></p></div><div><h3>Results</h3><p>LPS exposure dramatically down-regulated pulmonary expression of E-cadherin in mice, with profound loss of membrane E-cadherin in the airway epithelial cells and increased secretion of sE-cadherin in the airway lumen. At the same time, we found that the mitochondrial of airway epithelial cells in LPS-exposed mice exhibited significant morphological alterations that are hallmark features of ferroptosis, with smaller volume and increased membrane density. Other makers of ferroptosis were also detected, including increased cytoplasmic levels of iron and lipid peroxidates (MDA), as well as decreased GPX4 expression. 30 mg/kg of Lip-1 not only showed potent protective effects against the LPS-induced injury, inflammation, edema of the lung in those mice, but also rescued airway epithelial E-cadherin expression and decreased the release of sE-cadherin through inhibiting ferroptosis. While no noticeable changes induced by LPS were observed in mice treated with Lip-1 at 10 mg/kg nor Fer-1 at 1 mg/kg or 5 mg/kg.</p></div><div><h3>Conclusions</h3><p>Taken together, these data demonstrated that ferroptosis mediates airway epithelial E-cadherin dysfunction in LPS-induced ALI.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"84 ","pages":"Article 102284"},"PeriodicalIF":3.2,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139058621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of high dose N- Acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis: A randomised placebo-controlled pilot study 评估大剂量 N-乙酰半胱氨酸对成人支气管扩张症患者气道炎症和生活质量的影响:随机安慰剂对照试验研究。
IF 3.2 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2023-12-22 DOI: 10.1016/j.pupt.2023.102283
L. Jayaram , P.T. King , J. Hunt , M. Lim , C. Park , E. Hu , L. Dousha , P. Ha , J.B. Bartlett , A.M. Southcott , S. Muruganandan , S. Vogrin , M.A. Rees , O.M. Dean , C.A. Wong
{"title":"Evaluation of high dose N- Acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis: A randomised placebo-controlled pilot study","authors":"L. Jayaram ,&nbsp;P.T. King ,&nbsp;J. Hunt ,&nbsp;M. Lim ,&nbsp;C. Park ,&nbsp;E. Hu ,&nbsp;L. Dousha ,&nbsp;P. Ha ,&nbsp;J.B. Bartlett ,&nbsp;A.M. Southcott ,&nbsp;S. Muruganandan ,&nbsp;S. Vogrin ,&nbsp;M.A. Rees ,&nbsp;O.M. Dean ,&nbsp;C.A. Wong","doi":"10.1016/j.pupt.2023.102283","DOIUrl":"10.1016/j.pupt.2023.102283","url":null,"abstract":"<div><h3>Background</h3><p><span>High dose N acetylcysteine<span><span> (NAC), a mucolytic<span>, anti-inflammatory and antioxidant agent has been shown to significantly reduce exacerbations, and improve quality of life in placebo controlled, double blind randomised (RCT) studies </span></span>in patients<span> with COPD<span>, and in an open, randomised study in bronchiectasis. In this pilot, randomised, double-blind, placebo-controlled study, we wished to investigate the feasibility of a larger </span></span></span></span>clinical trial, and the anti-inflammatory and clinical benefits of high dose NAC in bronchiectasis.</p></div><div><h3>Aims</h3><p>Primary outcome: to assess the efficacy of NAC 2400 mg/day at 6 weeks on sputum<span> neutrophil elastase<span> (NE), a surrogate marker for exacerbations. Secondary aims included assessing the efficacy of NAC on sputum MUC5B, IL-8, lung function, quality of life, and adverse effects.</span></span></p></div><div><h3>Methods</h3><p>Participants were randomised to receive 2400 mg or placebo for 6 weeks. They underwent 3 visits: at baseline, week 3 and week 6 where clinical and sputum measurements were assessed.</p></div><div><h3>Results</h3><p><span>The study was stopped early due to the COVID pandemic. In total 24/30 patients were recruited, of which 17 completed all aspects of the study. Given this, a per protocol analysis was undertaken: NAC (n = 9) vs placebo (n = 8): mean age 72 vs 62 years; male gender: 44% vs 50%; baseline median FEV</span><sub>1</sub><span>1.56 L (mean 71.5 % predicted) vs 2.29L (mean 82.2% predicted). At 6 weeks, sputum NE fell by 47% in the NAC group relative to placebo (mean fold difference (95%CI: 0.53 (0.12,2.42); MUC5B increased by 48% with NAC compared with placebo. Lung function, FVC improved significantly with NAC compared with placebo at 6 weeks (mean fold difference (95%CI): 1.10 (1.00, 1.20), p = 0.045. Bronchiectasis Quality of life measures within the respiratory and social functioning domains demonstrated clinically meaningful improvements, with social functioning reaching statistical significance. Adverse effects were similar in both groups.</span></p></div><div><h3>Conclusion</h3><p>High dose NAC exhibits anti-inflammatory benefits, and improvements in aspects of quality of life and lung function measures. It is safe and well tolerated. Further larger placebo controlled RCT's are now warranted examining its role in reducing exacerbations.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"84 ","pages":"Article 102283"},"PeriodicalIF":3.2,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139014045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of high dose N- Acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis: A randomised placebo-controlled pilot study 评估大剂量 N-乙酰半胱氨酸对成人支气管扩张症患者气道炎症和生活质量的影响:随机安慰剂对照试验研究
IF 3.2 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2023-12-22 DOI: 10.1016/j.pupt.2023.102283
L. Jayaram, P.T. King, J. Hunt, M. Lim, C. Park, E. Hu, L. Dousha, P. Ha, J.B. Bartlett, Southcott Am, S. Muruganandan, S. Vogrin, M.A. Rees, O.M. Dean, C.A. Wong
{"title":"Evaluation of high dose N- Acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis: A randomised placebo-controlled pilot study","authors":"L. Jayaram, P.T. King, J. Hunt, M. Lim, C. Park, E. Hu, L. Dousha, P. Ha, J.B. Bartlett, Southcott Am, S. Muruganandan, S. Vogrin, M.A. Rees, O.M. Dean, C.A. Wong","doi":"10.1016/j.pupt.2023.102283","DOIUrl":"https://doi.org/10.1016/j.pupt.2023.102283","url":null,"abstract":"<h3>Background</h3><p>High dose N acetylcysteine (NAC), a mucolytic, anti-inflammatory and antioxidant agent has been shown to significantly reduce exacerbations, and improve quality of life in placebo controlled, double blind randomised (RCT) studies in patients with COPD, and in an open, randomised study in bronchiectasis. In this pilot, randomised, double-blind, placebo-controlled study, we wished to investigate the feasibility of a larger clinical trial, and the anti-inflammatory and clinical benefits of high dose NAC in bronchiectasis.</p><h3>Aims</h3><p>Primary outcome: to assess the efficacy of NAC 2400 mg/day at 6 weeks on sputum neutrophil elastase (NE), a surrogate marker for exacerbations. Secondary aims included assessing the efficacy of NAC on sputum MUC5B, IL-8, lung function, quality of life, and adverse effects.</p><h3>Methods</h3><p>Participants were randomised to receive 2400 mg or placebo for 6 weeks. They underwent 3 visits: at baseline, week 3 and week 6 where clinical and sputum measurements were assessed.</p><h3>Results</h3><p>The study was stopped early due to the COVID pandemic. In total 24/30 patients were recruited, of which 17 completed all aspects of the study. Given this, a per protocol analysis was undertaken: NAC (n = 9) vs placebo (n = 8): mean age 72 vs 62 years; male gender: 44% vs 50%; baseline median FEV<sub>1</sub>1.56 L (mean 71.5 % predicted) vs 2.29L (mean 82.2% predicted). At 6 weeks, sputum NE fell by 47% in the NAC group relative to placebo (mean fold difference (95%CI: 0.53 (0.12,2.42); MUC5B increased by 48% with NAC compared with placebo. Lung function, FVC improved significantly with NAC compared with placebo at 6 weeks (mean fold difference (95%CI): 1.10 (1.00, 1.20), p = 0.045. Bronchiectasis Quality of life measures within the respiratory and social functioning domains demonstrated clinically meaningful improvements, with social functioning reaching statistical significance. Adverse effects were similar in both groups.</p><h3>Conclusion</h3><p>High dose NAC exhibits anti-inflammatory benefits, and improvements in aspects of quality of life and lung function measures. It is safe and well tolerated. Further larger placebo controlled RCT's are now warranted examining its role in reducing exacerbations.</p>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"88 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139022393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effects of nirmatrelvir/ritonavir on tacrolimus levels in lung transplant recipients: A single-center study 尼马瑞韦/利托那韦对肺移植受者他克莫司水平的影响:单中心研究
IF 3.2 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2023-12-06 DOI: 10.1016/j.pupt.2023.102280
Xiaoxing Wang , Wenwen Du , Dan Zhang , Wenhui Chen , Xianbo Zuo
{"title":"The effects of nirmatrelvir/ritonavir on tacrolimus levels in lung transplant recipients: A single-center study","authors":"Xiaoxing Wang ,&nbsp;Wenwen Du ,&nbsp;Dan Zhang ,&nbsp;Wenhui Chen ,&nbsp;Xianbo Zuo","doi":"10.1016/j.pupt.2023.102280","DOIUrl":"10.1016/j.pupt.2023.102280","url":null,"abstract":"<div><h3>Background</h3><p><span><span>Lung transplant recipients (LTRs) have a higher risk of hospitalization and mortality due to COVID-19 compared with the immunocompetent population. The use of nirmatrelvir/ritonavir (NR), an effective oral treatment for COVID-19, is quite challenging due to its potent drug-drug interactions with </span>immunosuppressants<span><span> and azole </span>antifungals<span>. As there are few clinical reports of the use of NR in LTRs, we measured tacrolimus levels </span></span></span>in patients receiving NR in our hospital to improve safety when prescribing NR.</p></div><div><h3>Methods</h3><p><span>In total, 48 adult LTRs who received NR between November 19, 2022, and January 19, 2023, at China-Japan Friendship Hospital were retrospectively included and followed for 20 days after initiating NR. Tacrolimus was held at least 12 h before initiating NR and re-administered based on the trough levels after completing NR treatment. All concomitant medications, </span>drug concentrations, laboratory results, and genotypes were recorded and analyzed.</p></div><div><h3>Results</h3><p>Most patients showed stable tacrolimus trough levels despite high individual variability. Four patients exhibited supratherapeutic trough levels of tacrolimus (more than 15 ng/mL). Two patients who received 0.5 mg of tacrolimus during NR treatment had trough levels below 3.0 ng/mL. In addition, we found that in 13 patients, the trough levels were 130% of baseline after cessation of tacrolimus, and logistic regression revealed that increased trough level was significantly associated with age more than 60 years.</p></div><div><h3>Conclusions</h3><p>NR can be safely used in LTRs with close monitoring of tacrolimus levels and appropriate dose adjustments. However, more attention should be paid to elderly patients, as NR may more severely affect their drug metabolism. Due to the limited sample size, further studies are needed to guide the optimal use of tacrolimus following treatment with NR and explore the risk factors significantly affecting the interactions between NR and tacrolimus.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"84 ","pages":"Article 102280"},"PeriodicalIF":3.2,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138547215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can single-inhaler Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium therapy postpone or save biologics for severe asthma? 单吸入双丙酸倍氯米松/富马酸福莫特罗/甘替溴铵治疗能否延缓或挽救严重哮喘患者的生物制剂治疗?
IF 3.2 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2023-12-01 DOI: 10.1016/j.pupt.2023.102270
Silvano Dragonieri, Vitaliano Nicola Quaranta, Andrea Portacci, Giovanna Elisiana Carpagnano
{"title":"Can single-inhaler Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium therapy postpone or save biologics for severe asthma?","authors":"Silvano Dragonieri,&nbsp;Vitaliano Nicola Quaranta,&nbsp;Andrea Portacci,&nbsp;Giovanna Elisiana Carpagnano","doi":"10.1016/j.pupt.2023.102270","DOIUrl":"10.1016/j.pupt.2023.102270","url":null,"abstract":"<div><p><span>Inhaled corticosteroids, along with beta2-agonists and anti-muscarinics, represent the cornerstone of asthma treatment<span><span>. Although the advent of monoclonal antibodies has dramatically changed </span>severe asthma management, there are still patients ineligible or with poor response to biologics. Moreover, high costs associated with monoclonal antibodies prescription are still an open issue, leading clinicians to carefully assess cost-benefit ratio before their administration. From this perspective, the use of single-inhaler Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium </span></span>in patients with severe asthma could not only improve their clinical and functional performance, but also postpone biologic prescription, with positive repercussions on healthcare costs.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"83 ","pages":"Article 102270"},"PeriodicalIF":3.2,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138441166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信